Mario Balsa· @MarioBalsaMD · X·· 18 小时前评分70
正文 · 机器翻译
☝🏼#ESMO26 靶向治疗：毒性不仅仅取决于药物本身——具体情境也很重要。
💥 @NReguart 分享的关键要点：
• PD-(L)1 → osimertinib：严重 irAEs 15%；G≥3 肺炎 10%
• PD-(L)1 → sotorasib：洗脱期较短时，G≥3 肝毒性显著 ↑
• KRASi + IO：可行，但不同药物间的毒性差异显著
• 剂量调整 ≠ 治疗失败
@OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma
79 浏览 · 2 赞 · 2 转发 · 0 回复
会议摘要
2719RO按 Rapid oral 1: NSCLC, metastatic 对上
FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.orgLBA73按 Rapid oral 1: NSCLC, metastatic 对上
PACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line
https://esmocongress.esmo.org来源：Mario Balsa · x.com